Kurt Gustafson
Director of Finance/CFO chez OMNIAB, INC.
Fortune : 1 M $ au 31/03/2024
Profil
Kurt A.
Gustafson is currently serving as the Independent Director at Xencor, Inc. He is also the Chief Financial Officer & Executive VP-Finance at OmniAb Operations, Inc. and OmniAb, Inc. Previously, Mr. Gustafson held the position of Independent Non-Executive Director at Chromadex Corp.
from 2016 to 2022.
He was also the Chief Financial Officer & VP-Manufacturing Finance at Amgen, Inc. from 1991 to 2009.
Additionally, he served as the Chief Financial Officer & Executive Vice President at Spectrum Pharmaceuticals, Inc. from 2013 to 2022 and as the Chief Financial Officer & Vice President at Halozyme Therapeutics, Inc. from 2009 to 2013.
Mr. Gustafson started his career as a Staff Auditor at Horwath Velez & Co. PSC.
He also held the position of Chief Financial Officer & Vice President-Finance at Amgen Europe BV from 2004 to 2006 and Chief Financial Officer, Treasurer & VP at Amgen International AG.
Mr. Gustafson obtained an MBA from the University of California, Los Angeles and completed his undergraduate studies at North Park University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
OMNIAB, INC.
0,15% | 08/04/2024 | 176 697 ( 0,15% ) | 957 698 $ | 31/03/2024 |
XENCOR, INC.
0,01% | 06/03/2024 | 6 007 ( 0,01% ) | 132 935 $ | 31/03/2024 |
Postes actifs de Kurt Gustafson
| Sociétés | Poste | Début |
|---|---|---|
| XENCOR, INC. | Director/Board Member | 25/07/2014 |
| OMNIAB, INC. | Director of Finance/CFO | 01/03/2022 |
OmniAb Operations, Inc.
 OmniAb Operations, Inc. BiotechnologyHealth Technology OmniAb Operations, Inc. operates as a drug discovery company. It provides pharmaceutical industry partners access to antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform includes the Biological Intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse, that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company is headquartered in Emeryville, CA. | Director of Finance/CFO | 01/03/2022 |
Anciens postes connus de Kurt Gustafson
| Sociétés | Poste | Fin |
|---|---|---|
| CHROMADEX CORPORATION | Director/Board Member | 16/06/2022 |
| SPECTRUM PHARMACEUTICALS, INC. | Director of Finance/CFO | 18/03/2022 |
| HALOZYME THERAPEUTICS, INC. | Director of Finance/CFO | 20/05/2013 |
| AMGEN INC. | Director of Finance/CFO | 01/01/2009 |
Amgen Europe BV
 Amgen Europe BV Medical DistributorsDistribution Services Part of Amgen, Inc., Amgen Europe BV wholesales pharmaceutical products. The private company is based in Breda, Netherlands. | Director of Finance/CFO | 01/01/2006 |
Formation de Kurt Gustafson
| University of California, Los Angeles | Masters Business Admin |
| North Park University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 6 |
|---|---|
| AMGEN INC. | Health Technology |
| SPECTRUM PHARMACEUTICALS, INC. | Health Technology |
| HALOZYME THERAPEUTICS, INC. | Health Technology |
| XENCOR, INC. | Health Technology |
| CHROMADEX CORPORATION | Health Technology |
| OMNIAB, INC. | Commercial Services |
| Entreprise privées | 4 |
|---|---|
Horwath Velez & Co. PSC
 Horwath Velez & Co. PSC Miscellaneous Commercial ServicesCommercial Services Horwath Velez & Co. PSC is a private company based in Washington. | Commercial Services |
Amgen Europe BV
Amgen Europe BV Medical DistributorsDistribution Services Part of Amgen, Inc., Amgen Europe BV wholesales pharmaceutical products. The private company is based in Breda, Netherlands. | Distribution Services |
| Amgen International AG | |
OmniAb Operations, Inc.
OmniAb Operations, Inc. BiotechnologyHealth Technology OmniAb Operations, Inc. operates as a drug discovery company. It provides pharmaceutical industry partners access to antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform includes the Biological Intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse, that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company is headquartered in Emeryville, CA. | Health Technology |
